secwatch / observer
8-K filed April 1, 2025, 7:59 PM ET ticker ESPR CIK 0001434868
leadership confidence high sentiment neutral materiality 0.40

Esperion appoints Robert E. Hoffman to board; two directors resign effective June 1

Esperion Therapeutics, Inc.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Antonio M. Gotto, Jr., M.D., D.Phil.

Director
ESPR · Esperion Therapeutics, Inc.
Effective
2025-06-01
Filed
April 1, 2025, 7:59 PM ET
On April 1, 2025, Antonio M. Gotto, Jr., M.D., D. Phil. notified the Board of the Company of his decision to resign from the Board, including his position as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective June 1, 2025.
Departed

Nicole Vitullo

Director
ESPR · Esperion Therapeutics, Inc.
Effective
2025-06-01
Filed
April 1, 2025, 7:59 PM ET
On April 1, 2025, Nicole Vitullo notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) of her decision to resign from the Board, including her positions as a member of the Audit Committee of the Board (the “Audit Committee”) and Compliance Committee of the Board, effective June 1, 2025.
Appointed

Robert E. Hoffman

Director and Chairperson of the Audit Committee
ESPR · Esperion Therapeutics, Inc.
Effective
2025-04-01
Filed
April 1, 2025, 7:59 PM ET
On April 1, 2025, upon the recommendation of the Nominating and Corporate Governance Committee, the Board elected Robert E. Hoffman to the Board, effective April 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Antonio M. Gotto, Jr., M.D., D.Phil. resigned as Director at Esperion Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
On April 1, 2025, Antonio M. Gotto, Jr., M.D., D. Phil. notified the Board of the Company of his decision to resign from the Board, including his position as a member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), effective June 1, 2025.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Nicole Vitullo resigned as Director at Esperion Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
On April 1, 2025, Nicole Vitullo notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc. (the “Company”) of her decision to resign from the Board, including her positions as a member of the Audit Committee of the Board (the “Audit Committee”) and Compliance Committee of the Board, effective June 1, 2025.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Hoffman was elected as Director and Chairperson of the Audit Committee at Esperion Therapeutics, Inc..

Action
elected
Role
Director and Chairperson of the Audit Committee
Exact text from the filing
On April 1, 2025, upon the recommendation of the Nominating and Corporate Governance Committee, the Board elected Robert E. Hoffman to the Board, effective April 1, 2025.
View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001628280-25-015901
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.